⚡ Interrogation des APIs scientifiques en cours…
⚡ Interrogation des APIs scientifiques en cours…
Authors' conclusion
Does not affect the score
Publi-Score
Fidelity
Abstract (PubMed)
In a multicenter, double-blind, randomized, placebo-controlled, event-driven superiority trial (SELECT), 17,604 patients aged ≥45 years with preexisting cardiovascular disease and BMI ≥27 but no diabetes were randomly assigned to semaglutide 2.4 mg SC weekly or placebo. Mean follow-up was 39.8 months. A primary cardiovascular endpoint event (CV death, nonfatal MI, or nonfatal stroke) occurred in 6.5% in the semaglutide group vs 8.0% in the placebo group (HR 0.80, 95% CI 0.72–0.90, P<0.001). Adverse events leading to permanent discontinuation occurred in 16.6% (semaglutide) vs 8.2% (placebo).
Coeff. authors = avg(0.40, 0.80) = 0.60
Coeff. editorial = avg(1.00, 0.90) = 0.95
min(0.60, 0.95) = 0.60← lowest dominates
Final coefficient : 0.60
Final score = 55.8/100 × 0.60 × 100 = 34/100
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding JPH — 2021 · The New England Journal of Medicine
Contrasted resultsSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso SP — 2016 · The New England Journal of Medicine
Contrasted resultsUrinary sodium excretion, blood pressure, cardiovascular disease, and mortality: a comm…
Mente A — 2018 · Lancet (London, England)
Contrasted resultsLong-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follo…
Rothwell PM — 2010 · Lancet (London, England)
Contrasted resultsTriggering of acute myocardial infarction by heavy physical exertion. Protection agains…
Mittleman MA — 1993 · The New England journal of medicine